The oncology drug developer has raised $92.5m in VC funding, $11.5m of which came from MedImmune Ventures, the CVC unit that now owns a 16.7% stake.
US-based oncology therapy developer G1 Therapeutics has filed for a $115m initial public offering that will provide an exit for MedImmune, a subsidiary of pharmaceutical firm AstraZeneca.
G1 is developing anti-cancer therapeutics that will work as inhibitors of cyclin-dependent kinase, a family of proteins that certain kinds of tumours rely on to grow and spread. The IPO proceeds will support development of G1’s three main product candidates.
The company was spun out of North Carolina University’s Lineberger Comprehensive Cancer Center…
